Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

Journal:

The New England Journal of Medicine

Published:

2026-03-26

DOI:

10.1056/nejmoa2507874

Affiliations:

22

Authors:

23

Go to article

Institutions	Authors	Share
Mayo Clinic, United States of America (USA)	5.000000	0.22
OSU Department of Pediatrics (Nationwide Children's Hospital), United States of America (USA)	1.000000	0.04
University of Pittsburgh Medical Center (UPMC), United States of America (USA)	1.000000	0.04
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.04
Asklepios Klinik Altona, Germany	1.000000	0.04
St. Josef-Hospital, RUB, Germany	1.000000	0.04
Lehigh Valley Hospital - Cedar Crest, LVHN, United States of America (USA)	1.000000	0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.04
Missouri Baptist Medical Center, United States of America (USA)	1.000000	0.04
Baylor University Medical Center at Dallas, United States of America (USA)	1.000000	0.04
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.04
Nebraska Medicine, United States of America (USA)	1.000000	0.04
Duke University Health System, United States of America (USA)	1.000000	0.04
Ohio State University Wexner Medical Center (OSUWMC), United States of America (USA)	1.000000	0.04
Swedish Health Services, United States of America (USA)	1.000000	0.04
Virginia Commonwealth University (VCU), United States of America (USA)	1.000000	0.04
University of Colorado Cancer Center, United States of America (USA)	1.000000	0.04
Iowa-Wide Oncology Research Coalition (I-WORC NCORP), United States of America (USA)	1.000000	0.04
Alliance for Clinical Trials in Oncology, United States of America (USA)	0.500000	0.02
The University of Chicago (UChicago), United States of America (USA)	0.500000	0.02

Interested in Oncology and Carcinogenesis?